摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-氮杂双环[3.3.3]十一烷 | 31023-92-4

中文名称
1-氮杂双环[3.3.3]十一烷
中文别名
——
英文名称
manxine
英文别名
1-aza-bicyclo[3.3.3]undecane;1-Azabicyclo[3.3.3]undecane
1-氮杂双环[3.3.3]十一烷化学式
CAS
31023-92-4
化学式
C10H19N
mdl
——
分子量
153.268
InChiKey
WKPGJLQHSAOQEL-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    213.7±8.0 °C(Predicted)
  • 密度:
    0.93±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.2
  • 重原子数:
    11
  • 可旋转键数:
    0
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    3.2
  • 氢给体数:
    0
  • 氢受体数:
    1

安全信息

  • 海关编码:
    2933990090

SDS

SDS:f7b60e2006e563f426e6719a207cfea1
查看

上下游信息

反应信息

  • 作为反应物:
    描述:
    参考文献:
    名称:
    叔胺对三重态二苯甲酮的光还原作用:胺分子结构和酮基自由基收率†
    摘要:
    研究了14种叔胺对三重态二苯甲酮的光还原作用。酮基的产率与猝灭速率常数不相关,也不与胺的电子给体倾向相关。胺的单个结构特征似乎决定了光还原产率。
    DOI:
    10.1002/hlca.19970800309
点击查看最新优质反应信息

文献信息

  • GLYCOSYLATED VALPROIC ACID ANALOGS AND USES THEREOF
    申请人:HEYMAN Norman S.
    公开号:US20130029924A1
    公开(公告)日:2013-01-31
    Glycosylated valproic acid and its analogs are provided. In some embodiments, the glycosylated valproic acid and its analogs have improved solubility and are ideal for drug delivery to treat a variety of diseases.
    提供了糖基化的丙戊酸及其类似物。在某些实施方式中,糖基化的丙戊酸及其类似物具有改善的溶解性,并且非常适合用于药物输送以治疗各种疾病。
  • NITROGENOUS HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF
    申请人:Ochiai Hiroshi
    公开号:US20090233908A1
    公开(公告)日:2009-09-17
    A compound represented by formula (I): (wherein the symbols are the same as defined in the description), a salt thereof, an N-oxide thereof, a solvate thereof or a prodrug thereof, and medicinal use thereof. The compound represented by formula (I) has CXCR4 antagonistic activity. It is hence useful as, e.g., a preventive and/or therapeutic agent for CXCR4-mediated diseases such as inflammatory/immunologic diseases (e.g., rheumatoid arthritis, arthritis, retinopathy, pulmonary fibrosis, and rejection reactions of transplanted organs), allergic diseases, infections diseases (e.g., human immunodeficiency virus infection and acquired immunologic deficiency syndrome), psychoneurotic diseases, cerebral diseases, cardiac/vascular disease, metabolic diseases, cancer diseases (e.g., cancer, cancer metastasis) or as an agent for regeneration therapy.
    化合物的化学式为(I):(其中符号的定义与说明书中相同),其盐,N-氧化物,溶剂化合物或前药,以及其药用。化合物(I)具有CXCR4拮抗活性。因此,它可用作预防和/或治疗CXCR4介导疾病的药物,例如炎症/免疫疾病(例如类风湿性关节炎,关节炎,视网膜病变,肺纤维化和移植器官的排斥反应),过敏性疾病,感染性疾病(例如人类免疫缺陷病毒感染和获得性免疫缺陷综合症),心理神经疾病,脑部疾病,心血管疾病,代谢性疾病,癌症(例如癌症,癌症转移)或再生治疗剂。
  • Azetidine ring compounds and drugs comprising the same
    申请人:Habashita Hiromu
    公开号:US20070135402A1
    公开(公告)日:2007-06-14
    It is intended to provide compounds having EDG-5 antagonism. Because of having EDG-5 antagonism, compounds of the formula (I): wherein each symbol is as defined in the description; salts thereof, N-oxides thereof, solvates thereof or prodrugs thereof are useful as preventive and/or therapeutic agent for EDG-5 mediated diseases, for example, diseases caused by blood vessel contraction (e.g. cerebrovascular spasms disease, cardiovascular spasms diseases, coronary artery spasms disease, hypertension, pulmonary hypertension, renal diseases, myocardial infarction, angina pectoris, arrhythmia, portal hypertension, varicosity and the like), arteriosclerosis, pulmonary fibrosis, hepatic fibrosis, renal fibrosis, respiratory diseases (e.g. bronchial asthma, chronic obstructive pulmonary diseases and the like), nephropathy, diabetes, hyperlipemia and the like.
    本发明旨在提供具有EDG-5拮抗作用的化合物。由于具有EDG-5拮抗作用,式(I)中的化合物:其中每个符号如描述中所定义的,其盐,N-氧化物,溶剂化物或其前药,可用作预防和/或治疗EDG-5介导的疾病的药物,例如血管收缩引起的疾病(例如脑血管痉挛疾病,心血管痉挛疾病,冠状动脉痉挛疾病,高血压,肺动脉高压,肾脏疾病,心肌梗死,心绞痛,心律失常,门脉高压,静脉曲张等),动脉硬化,肺纤维化,肝纤维化,肾脏疾病(例如肾病,糖尿病,高脂血症等)和其他疾病。
  • Nitrogen-containing heterocyclic compounds and medicinal use thereof
    申请人:Habashita Hiromu
    公开号:US20070167459A1
    公开(公告)日:2007-07-19
    The compound represented by formulae (I) and (II), the salt thereof, the N-oxide thereof or the solvate thereof, or the prodrug thereof and the pharmaceutical composition comprising thereof have a CXCR4-regulating effect, and they are effective in treatment and prevention of various inflammatory disease, various allergic disease, acquired immunodeficiency syndrome infection with human immunodeficiency virus, or agents for regeneration therapy. (wherein ring A represents a nitrogen-containing heterocyclic group which may have a substituent(s); ring B represents a homocyclic group which may have a substituent(s) or a heterocyclic group which may have a substituent(s); and Y represents a hydrocarbon group which may have a substituent(s), a heterocyclic group which may have a substituent(s), an amino group which may be protected, a hydroxyl group which may be protected or a mercapto group which may be protected; T represents ring A or an amino group which may be protected.)
    式(I)和(II)所代表的化合物、其盐、N-氧化物或溶剂合物、或其前药,以及包含它们的制药组合物具有CXCR4调节作用,它们对各种炎症性疾病、各种过敏性疾病、艾滋病毒感染、或再生治疗剂具有治疗和预防作用。(其中环A代表可能具有取代基的含氮杂环基团;环B代表可能具有取代基的同环基团或可能具有取代基的杂环基团;Y代表可能具有取代基的碳氢基团、可能具有取代基的杂环基团、可能被保护的氨基、可能被保护的羟基或可能被保护的巯基;T代表环A或可能被保护的氨基。)
  • NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF
    申请人:HABASHITA Hiromu
    公开号:US20120156219A1
    公开(公告)日:2012-06-21
    The compound represented by formulae (I) and (II), the salt thereof, the N-oxide thereof or the solvate thereof, or the prodrug thereof and the pharmaceutical composition comprising thereof have a CXCR4-regulating effect, and they are effective in treatment and prevention of various inflammatory disease, various allergic disease, acquired immunodeficiency syndrome infection with human immunodeficiency virus, or agents for regeneration therapy. (wherein ring A represents a nitrogen-containing heterocyclic group which may have a substituent(s); ring B represents a homocyclic group which may have a substituent(s) or a heterocyclic group which may have a substituent(s); and Y represents a hydrocarbon group which may have a substituent(s), a heterocyclic group which may have a substituent(s), an amino group which may be protected, a hydroxyl group which may be protected or a mercapto group which may be protected; T represents ring A or an amino group which may be protected.)
    化合物(I)和(II)的化学式、其盐、N-氧化物或其溶剂化物,或其前药以及包含它们的制药组合物具有CXCR4调节作用,对各种炎症性疾病、各种过敏性疾病、人类免疫缺陷病毒感染的获得性免疫缺陷综合症,或再生治疗剂具有治疗和预防作用。(其中环A代表一个含氮杂环基团,可以有取代基;环B代表一个同环基团,可以有取代基或一个含氮杂环基团,可以有取代基;Y代表一个碳氢基团,可以有取代基,一个含氮杂环基团,可以有取代基,一个氨基可以被保护,一个羟基可以被保护或一个巯基可以被保护;T代表环A或一个氨基可以被保护。)
查看更多

同类化合物

(N-(2-甲基丙-2-烯-1-基)乙烷-1,2-二胺) (4-(苄氧基)-2-(哌啶-1-基)吡啶咪丁-5-基)硼酸 (11-巯基十一烷基)-,,-三甲基溴化铵 鼠立死 鹿花菌素 鲸蜡醇硫酸酯DEA盐 鲸蜡硬脂基二甲基氯化铵 鲸蜡基胺氢氟酸盐 鲸蜡基二甲胺盐酸盐 高苯丙氨醇 高箱鲀毒素 高氯酸5-(二甲氨基)-1-({(E)-[4-(二甲氨基)苯基]甲亚基}氨基)-2-甲基吡啶正离子 高氯酸2-氯-1-({(E)-[4-(二甲氨基)苯基]甲亚基}氨基)-6-甲基吡啶正离子 高氯酸2-(丙烯酰基氧基)-N,N,N-三甲基乙铵 马诺地尔 马来酸氢十八烷酯 马来酸噻吗洛尔EP杂质C 马来酸噻吗洛尔 马来酸倍他司汀 顺式环己烷-1,3-二胺盐酸盐 顺式氯化锆二乙腈 顺式吡咯烷-3,4-二醇盐酸盐 顺式双(3-甲氧基丙腈)二氯铂(II) 顺式3,4-二氟吡咯烷盐酸盐 顺式1-甲基环丙烷1,2-二腈 顺式-二氯-反式-二乙酸-氨-环己胺合铂 顺式-二抗坏血酸(外消旋-1,2-二氨基环己烷)铂(II)水合物 顺式-N,2-二甲基环己胺 顺式-4-甲氧基-环己胺盐酸盐 顺式-4-环己烯-1.2-二胺 顺式-4-氨基-2,2,2-三氟乙酸环己酯 顺式-2-甲基环己胺 顺式-2-(苯基氨基)环己醇 顺式-2-(氨基甲基)-1-苯基环丙烷羧酸盐酸盐 顺式-1,3-二氨基环戊烷 顺式-1,2-环戊烷二胺 顺式-1,2-环丁腈 顺式-1,2-双氨甲基环己烷 顺式--N,N'-二甲基-1,2-环己二胺 顺式-(R,S)-1,2-二氨基环己烷铂硫酸盐 顺式-(2-氨基-环戊基)-甲醇 顺-2-戊烯腈 顺-1,3-环己烷二胺 顺-1,3-双(氨甲基)环己烷 顺,顺-丙二腈 非那唑啉 靛酚钠盐 靛酚 霜霉威盐酸盐 霜脲氰